<DOC>
	<DOCNO>NCT00006269</DOCNO>
	<brief_summary>RATIONALE : Octreotide may effective prevent diarrhea cause treatment irinotecan . PURPOSE : Randomized phase III trial study effectiveness octreotide prevent diarrhea patient receive irinotecan metastatic colon cancer .</brief_summary>
	<brief_title>Octreotide Prevention Diarrhea Patients Receiving Irinotecan Metastatic Colon Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare incidence grade 2-4 diarrhea completion irinotecan patient metastatic colorectal cancer treat octreotide vs placebo . II . Compare duration diarrhea need irinotecan dose reduction/ delay hospitalization patient treat 2 regimen . III . Collect data tumor response 1 year survival patient treat 2 regimen . IV . Determine pharmacokinetics interaction irinotecan octreotide subset patient . OUTLINE : This randomize , double blind , placebo control , multicenter study . Patients stratify accord prior pelvic irradiation ( yes v ) , age ( 70 vs 70 ) , ECOG performance status ( 0 vs 1 2 ) . Patients randomize 1 2 treatment arm . Arm I : Patients receive octreotide intramuscularly ( IM ) . Beginning 10-14 day later , patient receive irinotecan IV 90 minute day 1 . Patients also receive octreotide IM day irinotecan . Arm II : Patients receive placebo IM . Beginning 10-14 day later , patient receive irinotecan arm I . Patients also receive placebo IM day irinotecan . Therapy continue every 3 week least 6 course absence disease progression unacceptable toxicity . Patients follow every 3 month year 1 . PROJECTED ACCRUAL : A total 300 patient ( 150 per arm ) accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically , cytologically , and/or radiographically proven metastatic colorectal cancer disease recurrence progression follow fluorouracil ( 5FU ) base chemotherapy Acceptable 5FU base regimen include capecitabine , 5FUuracil , floxuridine , S1 , eniluracil combine 5FU Acceptable 5FU modulate agent include levamisole leucovorin calcium Measurable evaluable disease No known brain leptomeningeal disease except previously irradiate lesion require corticosteroid asymptomatic PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : WBC least 3,000/mm3 Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9 g/dL Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) SGOT SGPT great 3 time ULN ( great 5 time ULN liver metastasis present ) Renal : Creatinine le 2.0 mg/dL Cardiovascular : No uncontrolled hypertension No unstable angina No congestive heart failure No myocardial infarction within past 6 month No serious cardiac arrhythmia Pulmonary : No interstitial pneumonia fibrosis Gastrointestinal : No symptomatic cholelithiasis No gastrointestinal disease may result nontherapy relate diarrhea Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No medical surgical disease may result nontherapy relate diarrhea No severe disease would preclude study No mental incapacity psychiatric illness would preclude study No uncontrolled diabetes mellitus No hypersensitivity octreotide excipients No active uncontrolled infection HIV negative No active second malignancy within past 5 year except nonmelanomatous skin cancer cervical carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No prior irinotecan At least 7 day since prior chemotherapy recover Endocrine therapy : See Disease Characteristics Radiotherapy : See Disease Characteristics Surgery : No ostomy Other : Greater 1 month since prior investigational agent No concurrent investigational agent No concurrent phenytoin , phenobarbital , valproic acid , antiepileptic therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>diarrhea</keyword>
</DOC>